Abstract
Introduction:
Neuropathic pain and spasticity after spinal cord injury represent significant but still unresolved problems, which cause considerable suffering and reduced quality of life for patients with spinal cord injury. Treatment of neuropathic pain and spasticity is complicated and patients often receive incomplete relief from present available and recommended treatment. Cannabinoids has shown efficacy on both neuropathic pain and spasticity in patients with spinal cord injury, but the studies one the topic has been too small to make a general conclusion for patients with spinal cord injury.
Aims:
To investigate the effect of Sativex (cannabinoid agonist given as an oral mucosal spray), on neuropathic pain and spasticity in patients with spinal cord injury.
Methods:
A randomized, double-blind, placebo-controlled crossover study. We will include 30 patients with neuropathic pain and 30 patients with spasticity. Because many patients have dual symptoms, we expect to include 50 patients. A numeric rating scale for pain intensity and spasticity (0-10 point) will be used to measure primary outcome.
Present status:
Due to recent changes by the Danish Health and Medicines Authority, it is presently illegal to drive when using Sativex, which impedes the inclusion of patients.
Neuropathic pain and spasticity after spinal cord injury represent significant but still unresolved problems, which cause considerable suffering and reduced quality of life for patients with spinal cord injury. Treatment of neuropathic pain and spasticity is complicated and patients often receive incomplete relief from present available and recommended treatment. Cannabinoids has shown efficacy on both neuropathic pain and spasticity in patients with spinal cord injury, but the studies one the topic has been too small to make a general conclusion for patients with spinal cord injury.
Aims:
To investigate the effect of Sativex (cannabinoid agonist given as an oral mucosal spray), on neuropathic pain and spasticity in patients with spinal cord injury.
Methods:
A randomized, double-blind, placebo-controlled crossover study. We will include 30 patients with neuropathic pain and 30 patients with spasticity. Because many patients have dual symptoms, we expect to include 50 patients. A numeric rating scale for pain intensity and spasticity (0-10 point) will be used to measure primary outcome.
Present status:
Due to recent changes by the Danish Health and Medicines Authority, it is presently illegal to drive when using Sativex, which impedes the inclusion of patients.
| Originalsprog | Engelsk |
|---|---|
| Publikationsdato | 2014 |
| Status | Udgivet - 2014 |